Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis
This is a prospective pilot study investigating exhaled breath condensate analyses to quantify the variability over time of various biomarkers associated with symptomatic pneumonitis.
Checked against the public recordLast updated Oct 11, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Other: Exhaled Breath Collection; Other: Blood sample
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age greater than or equal to 18 years old. * Clinically diagnosed or suspected Stage III non-small cell lung cancer to be treated with chemoradiotherapy as part of cancer treatment, as determined by the treating clinician. * Plan for treatment with definitive radiotherapy (≥60 Gy) with concurrent chemotherapy at the discretion of the treating radiation and medical oncologists. * Willing and able to tolerate exhaled breath collection. * Able to provide informed consent. Exclusion Criteria: * Systemic (oral, intravenous or intramuscular) corticosteroid use for any reason within 5 days of registration. * Prior radiotherapy directed at the chest (thoracic inlet superiorly to diaphragm inferiorly). * Any systemic antibiotic use within 2 weeks of registration.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Wake Forest Baptist Comprehensive Cancer CenterWinston-Salem, North Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 11, 2023. Always confirm current availability with the study team.